FDA Approves Orthovita's New Collagen Facility

Orthovita, Inc. (NASDAQ: VITA | PowerRating), an orthobiologics and biosurgery company, reported today that the U.S. Food and Drug Administration (FDA) approved Orthovita's PMA supplement for a new collagen processing facility in Malvern, Pennsylvania. Orthovita will use the new facility to process the highly purified form of collagen used in its VITAGEL(TM) Surgical Hemostat product. VITAGEL is a composite liquid hemostat used in surgical procedures as an adjunct to hemostasis when control of bleeding by ligature or conventional procedures is ineffective or impractical. VITAGEL is combined with the patient's own plasma immediately prior to application to a bleeding site. A fibrin/collagen clot forms quickly to control bleeding and provide a three-dimensional matrix to facilitate healing.

The approval of the new facility not only gives Orthovita enhanced control over the supply and quality of a key raw material for its VITAGEL product, but also provides the Company with an opportunity to develop, manufacture and market additional collagen-based products. This technology processes collagen to retain crucial aspects of its natural molecular structure and the potent biological characteristics found in the collagen of living tissues. As a result, the collagen processed at the facility will be among the purest available on the market.

Orthovita's President and Chief Executive Officer Antony Koblish stated, "We are very pleased to have further solidified our supply control over our VITAGEL product. The regulatory approval of our collagen facility also gives us another resource for executing on our goal to broaden our product offerings and increase sales force leverage. We are actively engaged in research and development work for products based on the versatile properties of the ultra pure collagen that can be made at our FDA-approved facility. We are also pursuing outside partnering and co-development arrangements to utilize our collagen facility and technical know-how."

Cardiva Medical, Inc. Announces U.S. Distribution for Hemostasis Products

SUNNYVALE, Calif., July 26 — /PRNewswire/ -- Cardiva Medical, Inc. announced today that it has signed an agreement with Advanced Vascular Dynamics to distribute several products used for postcatheterization femoral and radial artery hemostasis in the U.S. These products include i) RadAR™, an innovative radial artery compression device, ii) ComfortPress™, an ergonomic hand-held manual compression assist device, iii) ExpressAR™, an external mobile compression device and iv) Celox Vascular™, a chitosan based hemostatic patch.

"We are delighted to offer these unique products to our customers in the US," said John McCurdy, Vice President of Sales. McCurdy continued, "The products complement our Catalyst femoral artery closure system and will enable our customers to take advantage of economical alternatives for femoral and radial artery closure." RadAR, ComfortPress, ExpressAR and Celox Vascular are used in cardiac catheterization labs, interventional radiology departments and intensive care units. "This helps us extend our product lines to more customers and enhance our level of onsite customer service. We are very pleased to work with Cardiva," said Matthew Semler, President of Advanced Vascular Dynamics.